GlobeNewswire 11/03/2020 Dynavax Announces Fourth Quarter and Full Year 2019 Financial Results
GlobeNewswire 05/03/2020 Heather Rowe Armstrong Joins Arcutis as Vice President of Investor Relations and Corporate Communica...
GlobeNewswire 02/03/2020 Dynavax Announces Collaboration with the University of Queensland and the Coalition for Epidemic Pre...
GlobeNewswire 24/02/2020 Dynavax to Report Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Ma...
GlobeNewswire 18/02/2020 Dynavax to Present at the Cowen 40th Annual Health Care Conference
GlobeNewswire 16/12/2019 Dynavax Appoints Ryan Spencer as Chief Executive Officer and to Board of Directors
GlobeNewswire 05/12/2019 Dynavax Announces Partnership with Albertsons Companies’ Pharmacies to Offer HEPLISAV-B® Hepatitis B...
GlobeNewswire 03/12/2019 Dynavax Announces HEPLISAV-B Post-Marketing Requirement Interim Report Completed
GlobeNewswire 14/11/2019 Nurix Therapeutics Announces Key Management Additions
GlobeNewswire 07/11/2019 Dynavax to Present at the Stifel 2019 Healthcare Conference
GlobeNewswire 06/11/2019 Dynavax Announces Third Quarter 2019 Financial Results
GlobeNewswire 24/10/2019 Dynavax to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6
GlobeNewswire 30/09/2019 Dynavax to Present at the 2019 Cantor Global Healthcare Conference
GlobeNewswire 10/09/2019 Syapse Appoints Fletcher Payne as Chief Financial Officer
GlobeNewswire 10/09/2019 Vectura Group plc: Proposed Special Dividend and Share Consolidation, Share Buyback Programme and Di...
GlobeNewswire 12/08/2019 Dynavax Announces Andrew Hack, M.D., Ph.D., Has Joined Board of Directors
GlobeNewswire 08/08/2019 Dynavax Technologies Announces Pricing of $70.1 Million Public Offering of Common Stock, Non Voting ...
GlobeNewswire 07/08/2019 Dynavax Technologies Announces Proposed Public Offering of Common Stock, Non-Voting Preferred Stock ...
GlobeNewswire 07/08/2019 Dynavax Announces Second Quarter 2019 Financial Results
GlobeNewswire 24/07/2019 Dynavax Technologies to Report Second Quarter 2019 Financial Results and Host Conference Call on Aug...
GlobeNewswire 17/07/2019 Vectura confirms R&D investment priorities, announces a proposed £50 million capital return and a pr...
GlobeNewswire 03/06/2019 Dynavax to Present at the William Blair & Co. Annual Growth Stock Conference  
GlobeNewswire 03/06/2019 Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax’s SD-101 in Combination with...
GlobeNewswire 01/06/2019 Dynavax Presents Phase 2 Data on SD-101 in Combination with KEYTRUDA® (pembrolizumab) for Patients w...
TeleTrader 24/05/2019 Dynavax to focus on vaccine business